As gain-of-function mutations in NRAS are found in a minority of FVPTCs [5], overexpression of IGF2BP2 would be an intriguing alternative that leads to enhanced NRAS signalling in thyroid cancer with follicular histology. This evidence concerns the gene IGF2BP2 and thyroid gland carcinoma.